Quest Diagnostics (DGX-N) rallied from $73.02 in March 2020 (not shown) to $174.16 in December 2021 (A), reversed the trend in 2022 when it fell below the 40-week Moving Average (40wMA – B), and then settled in a large descending pattern made up of lower highs and support near $120 for about one year (dashed lines). The stock had a breakout from this formation (C) and above the 2022 high (shaded area) and reached a high of $178.87 in March (D) while trading above a rising trendline (solid line). Quest Diagnostics was overbought in March and far above the rising 40wMA. It has since started a pullback toward the average for a good entry level. There is good support near $160; only a sustained decline below this level would be negative. Point & Figure measurements provide targets of $180 and $195. Higher targets are visible. Monica Rizk is the Senior Technical Analyst of the Phases & Cycles publication (www.capitalightresearch.com). Chart source: www.decisionplus.com